Related Experiment Video
Updated: Mar 14, 2026
08:43
Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
Published on: January 31, 2020
7.4K
Anakinra in resistant gout: a case report.
Jana Van Wabeke1, Eric Dhondt1, Isabelle Peene1
1a Department of Rheumatology , AZ Sint-Jan Brugge AV, Campus Sint-Jan , Brugge , Belgium.
Acta Clinica Belgica
|October 8, 2016
Summary
Gout is a common inflammatory arthritis. Interleukin-1 inhibition with anakinra offers an effective treatment for severe gout cases unresponsive to traditional therapies.
Area of Science:
- Rheumatology
- Immunology
Background:
- Gout is a prevalent inflammatory arthritis characterized by crystal deposition.
- Standard treatments for acute gout flares include NSAIDs, colchicine, and corticosteroids.
- Interleukin-1 (IL-1) inhibition is an established alternative for refractory cases.
Observation:
- A 69-year-old female patient presented with severe polyarticular tophaceous gout.
- The patient's condition was refractory to conventional gout treatments.
Findings:
- Successful treatment of polyarticular tophaceous gout was achieved using anakinra.
- Anakinra, an IL-1 inhibitor, demonstrated efficacy in this challenging case.
Implications:
- This case highlights anakinra as a viable therapeutic option for complex gout.
- IL-1 inhibition may be crucial for managing severe, treatment-resistant gout.
- Further research into IL-1 blockade for gout management is warranted.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
693
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
693
01:29Inflammatory Bowel Disease IV: Pharmacological Management
893
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
893
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
636
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
636
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
593
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
593
01:23Gastritis III: Clinical Manifestations and Management
1.6K
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
1.6K
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
1.1K
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
1.1K